TNSN98155A1 - Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation - Google Patents

Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation

Info

Publication number
TNSN98155A1
TNSN98155A1 TNTNSN98155A TNSN98155A TNSN98155A1 TN SN98155 A1 TNSN98155 A1 TN SN98155A1 TN TNSN98155 A TNTNSN98155 A TN TNSN98155A TN SN98155 A TNSN98155 A TN SN98155A TN SN98155 A1 TNSN98155 A1 TN SN98155A1
Authority
TN
Tunisia
Prior art keywords
antihypertensitive
atorvastatin
agents
combinations
preparation
Prior art date
Application number
TNTNSN98155A
Other languages
English (en)
Inventor
Andrew Donald Scott Robert
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN98155A1 publication Critical patent/TNSN98155A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

L’INVENTION CONCERNE DES ASSOCIATIONS PHARMACEUTIQUES D’ATORVASTATINE OU D’UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET D’AGENTS ANTIHYPERTENSIFS. ELLE CONCERNE EGALEMENT UN PROCEDE POUR LEUR PREPARATION ET DES KITS CONTENANT SES ASSOCIATIONS. APPLICATION : UTILISATION DE CES ASSOCIATIONS POUR LE TRAITEMENT DE SUJETS SOUFFRANT D'ANGINE DE POITRINE, D'ATHEROSCLEROSE, D'HYPERTENSION ET D'HYPERLIPIDEMIE EN ASSOCIATION OU DE SUJETS PRESENTANT UN RISQUE CARDIAQUE
TNTNSN98155A 1997-08-29 1998-08-26 Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation TNSN98155A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5727697P 1997-08-29 1997-08-29

Publications (1)

Publication Number Publication Date
TNSN98155A1 true TNSN98155A1 (fr) 2005-03-15

Family

ID=22009602

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN98155A TNSN98155A1 (fr) 1997-08-29 1998-08-26 Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation

Country Status (41)

Country Link
US (2) US20020099046A1 (fr)
EP (1) EP1009400B1 (fr)
JP (2) JP2001514223A (fr)
KR (3) KR20030015394A (fr)
CN (3) CN1268053A (fr)
AP (1) AP1191A (fr)
AR (1) AR016399A1 (fr)
AT (1) ATE285767T1 (fr)
AU (1) AU740424B2 (fr)
BG (1) BG64724B1 (fr)
BR (1) BR9811556A (fr)
CA (1) CA2296723A1 (fr)
CO (1) CO4970724A1 (fr)
DE (1) DE69828413T2 (fr)
DZ (1) DZ2595A1 (fr)
EA (1) EA200000012A1 (fr)
EG (1) EG24678A (fr)
ES (1) ES2234134T3 (fr)
GT (1) GT199800126A (fr)
HR (1) HRP980474A2 (fr)
HU (1) HUP0004318A3 (fr)
ID (1) ID24118A (fr)
IL (2) IL133962A0 (fr)
IS (1) IS5341A (fr)
MA (1) MA26536A1 (fr)
MY (1) MY121008A (fr)
NO (1) NO323987B1 (fr)
NZ (2) NZ530630A (fr)
OA (1) OA11291A (fr)
PA (1) PA8457901A1 (fr)
PE (1) PE107099A1 (fr)
PL (1) PL339091A1 (fr)
PT (1) PT1009400E (fr)
SA (1) SA98190603B1 (fr)
SK (1) SK1432000A3 (fr)
TN (1) TNSN98155A1 (fr)
TR (1) TR200000563T2 (fr)
UY (1) UY25155A1 (fr)
WO (1) WO1999011260A1 (fr)
YU (1) YU2000A (fr)
ZA (1) ZA987839B (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
AU1591699A (en) * 1998-03-17 1999-10-11 Warner-Lambert Company Statin-matrix metalloproteinase inhibitor combinations
AU2007200367B2 (en) * 1999-02-06 2010-04-08 Astrazeneca Ab Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
ATE309807T1 (de) 1999-09-24 2005-12-15 Vasogen Ireland Ltd Zusammensetzung zur behandlung von atherosklerose,welche ein statin und ex-vivo behandeltes blut enthält
FR2803525B1 (fr) * 2000-01-06 2002-05-03 Sod Conseils Rech Applic Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
SE0002354D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
AU2001289672B2 (en) 2000-07-19 2005-12-08 Novartis Ag Valsartan salts
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
US7018649B2 (en) * 2000-10-23 2006-03-28 Euro-Celtique, S.A. Felodipine transdermal device and methods
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
DE60220522T2 (de) * 2001-07-19 2007-09-27 Pharmacia Corp. Kombination von einem aldosterone rezeptor antagonisten und einem hmg coa reduktase hemmer
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
US6852737B2 (en) 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
ATE395936T1 (de) * 2002-06-20 2008-06-15 Univ Alberta Dichloracetat in kombination mit kardioprotektiven oder hämodynamischen medikamenten
WO2004002472A1 (fr) * 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Hydobromure de carvedilol
JP2005533823A (ja) * 2002-06-27 2005-11-10 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド リン酸カルベジロール塩および／またはその溶媒和物、対応する組成物、および／または治療方法
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
GB0221579D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Combinations of atorvastatin and, adrenergic receptor antagonists
AU2003274004A1 (en) * 2002-10-16 2004-05-04 Recordati Ireland Limited Lisinopril/lercanidipine combination therapy
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
EP1686986A4 (fr) * 2003-11-25 2009-05-27 Sb Pharmco Inc Sels de carvedilol, compositions correspondantes, procedes d'administration et/ou de traitement
EP1686967A4 (fr) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd Base libre de carvedilol, ses sels, formes anhydres ou solvats, compositions pharmaceutiques correspondantes, formulations a liberation controlee, et methodes de traitement ou d'administration
JP5072364B2 (ja) * 2003-11-25 2012-11-14 スミスクライン ビーチャム （コーク） リミテッド カルベジロール遊離塩基、カルベジロール塩、無水形態またはその溶媒和物、対応する医薬組成物、制御放出処方および治療またはデリバリー方法
KR20050092519A (ko) * 2004-03-16 2005-09-22 화이자 인코포레이티드 아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합
EP1734958A1 (fr) * 2004-04-06 2006-12-27 Merck & Co., Inc. Methodes destinees a traiter l'hypertension
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
CA2578224A1 (fr) * 2004-08-25 2006-03-09 Essentialis, Inc. Formulations pharmaceutiques d'activateurs de canaux potassiques atp, et utilisations correspondantes
US20080070926A1 (en) * 2005-02-17 2008-03-20 Roberto Fogari Therapeutic Combinations of Manidi Pine and a Statin
CN101415425B (zh) 2006-03-29 2014-11-26 兴和株式会社 甘油三酯降低剂和高胰岛素血症改善剂
US8642083B2 (en) * 2006-10-30 2014-02-04 Hanall Biopharma Co., Ltd. Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
US20110117194A1 (en) 2008-04-29 2011-05-19 Hanall Biopharma Co., Ltd. Pharmaceutical formulation containing angiotensin-ii receptor blocker
CZ2008740A3 (cs) * 2008-11-24 2010-01-06 Zentiva, A.S. Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem
WO2010085014A1 (fr) 2009-01-23 2010-07-29 Hanmi Pharm. Co., Ltd. Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procédé de fabrication
SI23149A (sl) * 2009-09-21 2011-03-31 Silverstone Pharma Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni
RU2481124C1 (ru) * 2011-10-27 2013-05-10 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения
CN102671198A (zh) * 2011-12-17 2012-09-19 东莞达信生物技术有限公司 一种降压降脂复方药及其制备方法
KR20140028971A (ko) * 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
CN105163734A (zh) * 2013-03-12 2015-12-16 株式会社Lg生命科学 包含缬沙坦及罗舒伐他汀钙的复合制剂及其制造方法
CN104173420A (zh) * 2013-05-20 2014-12-03 广州诺氏刘生物科技有限公司 一种治疗急性肾衰竭的药物
WO2016065103A1 (fr) 2014-10-23 2016-04-28 Arena Pharmaceuticals, Inc. Procédé de traitement de troubles liés au récepteur pgi2
KR20170003459A (ko) * 2015-06-30 2017-01-09 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
FR3040303B1 (fr) * 2015-08-27 2019-04-05 Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca
CN105232555A (zh) * 2015-11-19 2016-01-13 哈尔滨圣吉药业股份有限公司 一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法
EP3463322A4 (fr) * 2016-06-02 2019-11-20 Ana Pharmaceuticals, Inc. Méthodes et compositions pour le traitement d'une hypercalciurie et d'un calcul néphritique
JP2020506180A (ja) 2017-01-25 2020-02-27 ザ ジョージ インスティテュート フォー グローバル ヘルス 高血圧症の処置のための組成物
ES2897024T3 (es) 2017-03-01 2022-02-28 Arena Pharm Inc Composiciones que comprenden agonistas del receptor de PGI2 y procesos para la preparación de las mismas
US20200030296A1 (en) * 2018-07-26 2020-01-30 The George Institute for Global Health Compositions for the treatment of hypertension
CN112826937B (zh) * 2021-03-25 2022-03-22 山东大学齐鲁医院 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
RU2158607C2 (ru) * 1995-07-03 2000-11-10 Санкио Компани Лимитед Лечение артериосклероза и ксантомы
DE69636783T2 (de) * 1995-11-02 2007-10-18 Warner-Lambert Co. Llc Verfahren und pharmazeutische zusammensetzung zur regelung der lipidkonzentration

Also Published As

Publication number Publication date
IL133962A (en) 2006-07-05
IL133962A0 (en) 2001-04-30
BG104075A (en) 2000-09-29
GT199800126A (es) 2000-01-29
EG24678A (en) 2010-04-27
TR200000563T2 (tr) 2000-07-21
MA26536A1 (fr) 2004-12-20
AP9801332A0 (en) 1998-09-30
US20030199492A1 (en) 2003-10-23
ZA987839B (en) 2000-02-28
UY25155A1 (es) 2000-12-29
OA11291A (en) 2003-08-25
JP2005041875A (ja) 2005-02-17
EA200000012A1 (ru) 2000-08-28
AP1191A (en) 2003-07-19
EP1009400A1 (fr) 2000-06-21
US20020099046A1 (en) 2002-07-25
CN1268053A (zh) 2000-09-27
HRP980474A2 (en) 1999-06-30
ES2234134T3 (es) 2005-06-16
NO20000996L (no) 2000-04-27
MY121008A (en) 2005-12-30
NZ502280A (en) 2002-11-26
BG64724B1 (bg) 2006-01-31
DE69828413T2 (de) 2005-12-08
AR016399A1 (es) 2001-07-04
IS5341A (is) 2000-01-14
SA98190603B1 (ar) 2006-07-04
YU2000A (sh) 2002-12-10
EP1009400B1 (fr) 2004-12-29
ATE285767T1 (de) 2005-01-15
CN1473567A (zh) 2004-02-11
KR20010022477A (ko) 2001-03-15
KR20030015394A (ko) 2003-02-20
CA2296723A1 (fr) 1999-03-11
KR20040106591A (ko) 2004-12-17
CO4970724A1 (es) 2000-11-07
PL339091A1 (en) 2000-12-04
SK1432000A3 (en) 2000-12-11
AU8458998A (en) 1999-03-22
PT1009400E (pt) 2005-02-28
BR9811556A (pt) 2000-08-22
AU740424B2 (en) 2001-11-01
PE107099A1 (es) 1999-11-06
ID24118A (id) 2000-07-06
NO323987B1 (no) 2007-07-30
JP2001514223A (ja) 2001-09-11
HUP0004318A3 (en) 2002-10-28
HUP0004318A2 (hu) 2001-05-28
DE69828413D1 (de) 2005-02-03
PA8457901A1 (es) 2000-05-24
CN1473566A (zh) 2004-02-11
NZ530630A (en) 2005-05-27
WO1999011260A1 (fr) 1999-03-11
DZ2595A1 (fr) 2003-02-22
NO20000996D0 (no) 2000-02-28

Similar Documents

Publication Publication Date Title
TNSN98155A1 (fr) Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation
TNSN98156A1 (fr) Associations pharmaceutiques d'amlodipine et d'atorvastatine et procede pour leur preparation
TNSN98158A1 (fr) Associations pharmaceutiques d'amlodipine et d'une statine, et procede pour leur preparation
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00110A1 (fr) Sel mutuel d'amlodipine et d'atorvastatine, procede pour sa preparation et compositions pharmaceutiques le contenant
TNSN97193A1 (fr) Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN01125A1 (fr) Compositions pharmaceutiques comprenant un inhibiteur de cetp et de l'atorvastatine
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98025A1 (fr) Derives d'acide arylsulfonylhydroxamique, procede pour leur preparation et compositions les contenant.
TNSN98150A1 (fr) Derives d'acides aryloxyarylsulfonylaminohydroxamiques ; procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN96104A1 (fr) Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant
CA2206837A1 (fr) Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
TNSN98083A1 (fr) Derives de 6-0 methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99053A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant
TNSN99172A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99006A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99126A1 (fr) Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99110A1 (fr) Inhibiteurs non peptidiques de l'adhesion cellulaire sous la dependance de vla-4, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97087A1 (fr) 4(3h)-quinazolinones 2,3-disubstituees nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98035A1 (fr) Atropisomeres de 3-aryl-4(3h)-quinazolinones, procede pour leur preparation et compositions les contenant
TNSN99214A1 (fr) Azalides nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98024A1 (fr) 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN00235A1 (fr) Derives d'heterocyclo-alkylsulfonylpyrazole nouveaux, procede pour leur preparation et compositions les contenant
TNSN98127A1 (fr) Derives d'azetidinylpropylpiperidine , procede pour leur preparation et compositions pharmaceutiques les contenant.